[Skip to Content]
[Skip to Content Landing]
Citations 0
Poster Presentations: American Head and Neck Society
August 2006

P197 Combining the Proteasome Inhibitor Bortezomib With Reirradiation in Patients With Recurrent Head and Neck Squamous Cell Carcinoma

Author Affiliations

National Institutes of Health, Bethesda, Md

Arch Otolaryngol Head Neck Surg. 2006;132(8):903. doi:10.1001/archotol.132.8.903-b

Objective: The transcription factor nuclear factor 3BAB (NF-3BAB) promotes cell survival and radioresistance in head and neck squamous cell carcinoma (HNSCC). Our objective was to study bortezomib, a small-molecule inhibitor of proteasome activity that disrupts the degradation of inhibitor 3BAB (I3BAB) and activation of NF-3BAB, for potential cytotoxic and radiosensitizing activity in recurrent HNSCC.

Design: During a dose-escalation phase 1 clinical trial, clinical effects of proteasome inhibition and antitumor response were evaluated. Serial tumor biopsy specimens were collected before and 24 hours after bortezomib treatment alone, and immunohistochemical staining of p65NF-kB and other biomarkers was conducted.

First Page Preview View Large
First page PDF preview
First page PDF preview